Preexisting or therapy-induced mutations in relapsed acute lymphoblastic leukemia?-Reference-Cited by-同舟云学术

Preexisting or therapy-induced mutations in relapsed acute lymphoblastic leukemia?

Published:2020-11-05 Issue:19 Volume:136 Page:2233-2235
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Gaynon Paul S.¹²,Orgel Etan¹²^ORCID,Ji Lingyun²³^ORCID

Affiliation:

1. Cancer and Blood Disease Institute, Children’s Hospital Los Angeles, Los Angeles, CA; and

2. Keck School of Medicine and

3. Department of Preventive Medicine, University of Southern California, Los Angeles, CA

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/136/19/2233/1780387/bloodbld2020005258.pdf

Reference20 articles.

1. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia;Li;Blood,2020

2. Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): a Children’s Oncology Group (COG) study [abstract];Rheingold;J Clin Oncol,2019

3. A randomized phase 3 trial of blinatumomab vs. chemotherapy as post-reinduction therapy in high and intermediate risk (HR/IR) first relapse of B-acute lymphoblastic leukemia (B-ALL) in children and adolescents/young adults (AYAs) demonstrates superior efficacy and tolerability of blinatumomab: a report from Children’s Oncology Group Study AALL1331 [abstract];Brown;Blood,2019

4. Outcome of central nervous system relapses in childhood acute lymphoblastic leukaemia–prospective open cohort analyses of the ALLR3 trial;Masurekar;PLoS One,2014

5. Relapse-fated latent diagnosis subclones in acute B lineage leukemia are drug tolerant and possess distinct metabolic programs;Dobson;Cancer Discov,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Latest Contributions of Genomics to T-Cell Acute Lymphoblastic Leukemia (T-ALL);Cancers;2022-05-17

2. Therapy-induced mutagenesis in relapsed ALL is supported by mutational signature analysis;Blood;2020-11-05